Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 4—April 2022
Research Letter

Recurrent SARS-CoV-2 RNA Detection after COVID-19 Illness Onset during Pregnancy

Isabel Griffin, Kate R. WoodworthComments to Author , Romeo R. Galang, Veronica K. Burkel, Varsha Neelam, Samantha Siebman, Jerusha Barton, Susan E. Manning, Kathryn Aveni, Nicole D. Longcore, Elizabeth M. Harvey, Van Ngo, Deborah Mbotha, Sarah Chicchelly, Mamie Lush, Valorie Eckert, Paula Dzimira, Ayomide Sokale, Miguel Valencia-Prado, Eduardo Azziz-Baumgartner, Adam MacNeil, Suzanne M. Gilboa, and Van T. Tong
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (I. Griffin, K.R. Woodworth, R.R. Galang, V.K. Burkel, V. Neelam, E. Azziz-Baumgartner, A. MacNeil, S.M. Gilboa, V.T. Tong); Minnesota Department of Health, St. Paul, Minnesota, USA (S. Siebman); Georgia Department of Public Health, Atlanta (J. Barton); Massachusetts Department of Public Health, Boston, Massachusetts, USA (S.E. Manning); New Jersey Department of Health, Trenton, New Jersey, USA (K. Aveni); New York State Department of Health, Albany, New York, USA (N.D. Longcore); Tennessee Department of Health, Smithville, Tennessee, USA (E.M. Harvey); Los Angeles County Department of Public Health, Los Angeles, California, USA (V. Ngo); Washington State Department of Health, Tumwater, Washington, USA (D. Mbotha); Kansas Department of Public Health, Wichita, Kansas, USA (S. Chicchelly); Nebraska Department of Health and Human Services, Lincoln, Nebraska, USA (M. Lush); California Department of Public Health, Sacramento, California, USA (V. Eckert); Pennsylvania Department of Health, Harrisburg, Pennsylvania, USA (P. Dzimira); Philadelphia Department of Public Health, Philadelphia, Pennsylvania, USA (A. Sokale); Puerto Rico Department of Health, Bo. Monacillos Río Piedras, Puerto Rico, USA (M. Valencia-Prado)

Main Article


Symptomatic pregnant persons with SARS-CoV-2 infection detected in respiratory specimens by recurrent positive status, based on RT-PCR positive test result >90 d after symptom onset, Surveillance for Emerging Threats to Mothers and Babies Network, United States, March 29–December 31, 2020*

Characteristic Total, N = 6,551 Not recurrent, n = 6,409 Recurrent positive, n = 142
Median duration of RT-PCR positivity (range), d
3 (0–416)
3 (0–90)
127 (91–416)
Median duration of RNA shedding (range), d†
135 (0–441)
148 (0–441)
143 (18–412)
Median age at first positive result (IQR), y
29 (25–33)
29 (25–33)
29 (25–32)
Age at initial infection, y‡
<25 1,547 (23.6) 1,512 (23.6) 35 (25.6)
25–29 2,034 (31.0) 1,990 (31.0) 44 (40.0)
30–34 1,857 (28.4) 1,809 (28.2) 48 (33.8)
1,113 (17.0)
1,098 (17.1)
15 (10.6)
White non-Hispanic 2,599 (39.7) 2,554 (39.8) 45 (31.7)
Asian non-Hispanic 275 (4.2) 270 (4.2) 5 (3.5)
Black non-Hispanic 1,197 (18.3) 1,171 (18.3) 26 (18.3)
Hispanic 2,077 (31.7) 2,029 (31.7) 48 (33.8)
Multiple or other non-Hispanic 210 (3.2) 200 (3.1) 10 (7.1)
193 (2.9)
185 (2.9)
8 (5.6)
Trimester of SARS-CoV-2 infection§
First 1,146 (17.5) 1,114 (17.4) 32 (22.5)
Second 2,327 (35.5) 2,231 (34.8) 96 (67.6)
3,078 (47.0)
3,064 (47.8)
14 (9.9)
Underlying conditions¶
Yes 4,945 (74.4) 1,478 (25.6) 10 (7.0)
No 1,488 (22.7) 4,184 (72.4) 131 (92.3)
Unknown 118 (1.8) 117 (2.0) 1 (0.7)

*Values are no. (%) except as indicated. IQR, interquartile range; RT-PCR, reverse transcription PCR; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. †Duration of RNA shedding was available for only 458 persons. ‡Age in years at initial infection was calculated based on date of first SARS-CoV-2–positive test result during pregnancy or symptom onset if date of positive is unavailable. §Trimester of SARS-CoV-2 infection is calculated based on date of last menstrual period and either date of first positive SARS-CoV-2 results or symptom onset if date of positive unavailable. ¶Presence of any underlying condition was defined as any of the following: obesity, chronic lung disease, hypertension, diabetes, cardiovascular disease, or immunosuppressive conditions (conditions that weaken the immune system [e.g., HIV or AIDS, some cancers such as leukemia] or medications [e.g., chemotherapy or radiation treatment, chronic corticosteroids, or other immunosuppressive medications]).

Main Article

Page created: January 31, 2022
Page updated: March 19, 2022
Page reviewed: March 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.